2023

1. A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma

   British Journal of Cancer, Vol. 129, Núm. 5, pp. 811-818